Skip to main content
Smart Investors Daily
HR

NASDAQ · HROW

Harrow Health, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$29.09

Down-$1.03 (-3.42%)

Updated Nov 17, 2026, 4:11 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.89B
P/E ratio
-183.74
Dividend yield
0.00%
52-week range
$25.76 – $47.50
Volume
474.25K
Avg. volume
738.98K

Price performance · HROW

HROW price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

HROW closed at $29.09 after 21 trading sessions, up 5.09% for the selected period.

Last close
$29.09
Period change
+5.09%
Period low
$26.04
Period high
$30.36
Daily close
View OHLC price history
HROW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$29.65$30.39$29.00$29.09474.25K
Nov 13, 2026$28.37$31.10$28.31$30.12736.43K
Nov 12, 2026$29.54$29.54$28.16$28.30551.15K
Nov 11, 2026$29.88$30.5158$28.60$29.37979.49K
Nov 10, 2026$33.065$33.6799$28.9114$30.362.15M
Nov 9, 2026$27.05$27.84$26.1432$27.471.17M
Nov 6, 2026$26.40$26.94$25.76$26.89650.86K
Nov 5, 2026$28.71$28.71$25.97$26.04701.97K
Nov 4, 2026$28.41$29.535$28.38$28.75778.03K
Nov 3, 2026$28.21$28.98$27.81$28.54625.37K
Nov 2, 2026$28.38$28.91$27.29$28.20742.63K
Oct 30, 2026$29.69$30.05$28.0825$28.24335.28K
Oct 29, 2026$29.90$30.28$29.6058$29.99321.08K
Oct 28, 2026$28.96$29.74$28.70$29.39327.33K
Oct 27, 2026$29.10$29.57$28.435$29.07635.45K
Oct 26, 2026$28.61$29.48$28.30$28.95499.15K
Oct 23, 2026$27.76$28.555$27.14$28.44854.71K
Oct 22, 2026$27.82$28.45$27.702$28.15440.12K
Oct 21, 2026$28.26$28.66$27.98$28.24524.42K
Oct 20, 2026$27.70$29.25$27.70$28.07526.97K
Oct 19, 2026$27.40$28.53$27.40$27.68576.13K

Latest HROW news

The latest Smart Investors Daily articles mentioning HROW.

HROW research

Overview

Company profile and research snapshot.

Company profile

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$73.00
Implied upside
—
Analysts
—
HROW recent ratings
DateFirmRatingTarget
Nov 11, 2026BTIGBuy—
Oct 7, 2026BTIGBuy—
Sep 9, 2026Leerink PartnersOutperform—
Aug 11, 2026BTIGBuy—
Jul 21, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Yahoo · Nov 9, 2026

Harrow: Q3 Earnings Snapshot

(HROW) on Monday reported third-quarter net income of $9.The Nashville, Tennessee-based company said it had profit of 25 cents per share.

Yahoo · Nov 9, 2026

Harrow Announces Third Quarter 2026 Financial Results

Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over yearBranded revenue of $83.5 million, up 62% year over year and approximately 84% of total revenueGAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, compared with a net loss of $17.3 million in the second quarter of 2026 and net income of $1.0 million in the third quarter of 2025Adjusted EBITDA (a non-GAAP measure) of $21.2 million, c

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.